Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT

Schlenter, Marsha; Berneking, Vanessa; Krenkel, Barbara; Mottaghy, Felix M.; Vögeli, Thomas-Alexander; Eble, Michael J.; Pinkawa, Michael

doi:10.1007/s00066-018-1282-6

Cited by 19 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies reporting QoL after a follow-up of more than 5 years in relation to baseline values are hardly available [6]. As radiotherapy is known to have effects even many years after treatment, long-term effects on QoL are of high practical relevance [7].…”

Section: Introductionmentioning

confidence: 99%

Quality of life more than 10 years after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose

et al. 2020

Self Cite

View full text Add to dashboard Cite

Purpose Analysis of quality of life changes after radiotherapy with focus on the impact of time after treatment and prescription dose. Methods Consecutive patients were treated with doses from 70.2/1.8 Gy (n = 206) to 72/1.8–2.0 Gy (n = 176) in a single centre and surveyed using the Expanded Prostate Cancer Index Composite questionnaire. Results Urinary and bowel bother scores decreased 1 / 3 / 6 points and 7 / 7 / 9 points on average 1 / 5 / 10 years after RT in comparison to baseline scores. The rate of urinary (need of pads in 8% vs. 15% before vs. 10 years after RT; p = 0.01) and bowel (uncontrolled leakage of stool in 5% vs. 12% before vs. 10 years after RT; p < 0.01) incontinence, as well as rectal bleeding (4% vs. 8% before vs. 10 years after RT; p = 0.05) increased. Sexual function scores decreased (erections sufficient for intercourse in 36% vs. 12% before vs. 10 years after RT; p < 0.01). A higher dose had a statistically significant impact on urinary bother and stool incontinence, but also tended to decrease urinary continence. Age and comorbidities did not have an influence on score changes, but on baseline urinary function/bother and baseline sexual function. Conclusion Apart from an increasing rate of erectile dysfunction, urinary and bowel incontinence rates increased with increasing follow-up period. A higher dose was found to be associated with increased urinary problems and larger stool incontinence rates. Age and comorbidities were found to be relevant for baseline scores, but not for score changes.

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of life more than 10 years after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The presented results suggest that the implementation of this approach in intermediate and high-risk prostate cancer patients improves tumor control while keeping side effects at a reasonable level. Although some groups based the delineation of the boost volume on PET imaging [ 4 , 5 ], multiparametric (mp) magnetic resonance imaging (MRI) has become the preferred method for this purpose [ 8 , 9 ]. Recently, simplified biparametric (bp) protocols which do not require contrast medium injection have been demonstrated to yield similar results to full protocols, thus allowing shorter acquisition times and a broader access to this imaging modality [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer

et al. 2018

View full text Add to dashboard Cite

Purpose Accurate prostate cancer (PCa) detection is essential for planning focal external beam radiotherapy (EBRT). While biparametric MRI (bpMRI) including T2-weighted (T2w) and diffusion-weighted images (DWI) is an accurate tool to localize PCa, its value is less clear in the case of additional androgen deprivation therapy (ADT). The aim of this study was to investigate the value of a textural feature (TF) approach on bpMRI analysis in prostate cancer patients with and without neoadjuvant ADT with respect to future dose-painting applications. Methods 28 PCa patients (54–80 years) with ( n = 14) and without ( n = 14) ADT who underwent bpMRI with T2w and DWI were analyzed retrospectively. Lesions, central gland (CG), and peripheral zone (PZ) were delineated by an experienced urogenital radiologist based on localized pre-therapeutic histopathology. Histogram parameters and 20 Haralick TF were calculated. Regional differences (i. e., tumor vs. PZ, tumor vs. CG) were analyzed for all imaging parameters. Receiver-operating characteristic (ROC) analysis was performed to measure diagnostic performance to distinguish PCa from benign prostate tissue and to identify the features with best discriminative power in both patient groups. Results The obtained sensitivities were equivalent or superior when utilizing the TF in the no-ADT group, while specificity was higher for the histogram parameters. However, in the ADT group, TF outperformed the conventional histogram parameters in both specificity and sensitivity. Rule-in and rule-out criteria for ADT patients could exclusively be defined with the aid of TF. Conclusions The TF approach has the potential for quantitative image-assisted boost volume delineation in PCa patients even if they are undergoing neoadjuvant ADT. Electronic supplementary material The online version of this article (10.1007/s00066-018-1402-3) contains supplementary material, which is available to authorized users.

show abstract

“…By its ability to capture tumour heterogeneity through multimodal images, radiomics could therefore be extremely helpful. 15 Most DP clinical trials have been conducted using functional imaging with PET to delineate the biological target volume, [47][48][49][50] based on SUV thresholds or manual delineations. Although the number of patients included is still limited and the clinical benefit of PET-based dose painting still needs to be confirmed, the concept is promising.…”

Section: Radiomics For Delineation and Dose Prescriptionmentioning

confidence: 99%

Radiomics for radiation oncologists: are we ready to go?

et al. 2020

View full text Add to dashboard Cite

Radiomics have emerged as an exciting field of research over the past few years, with very wide potential applications in personalised and precision medicine of the future. Radiomics-based approaches are still however limited in daily clinical practice in oncology. This review focus on how radiomics could be incorporated into the radiation therapy pipeline, and globally help the radiation oncologist, from the tumour diagnosis to follow-up after treatment. Radiomics could impact on all steps of the treatment pipeline, once the limitations in terms of robustness and reproducibility are overcome. Major ongoing efforts should be made to collect and share data in the most standardised manner possible.

show abstract

Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT

Abstract: The first long-term analysis of patients treated with SIB based on molecular imaging with 18-F-choline-PET/CT showed an excellent biochemical recurrence-free survival, but a larger percentage of bowel problems in comparison to the control group.

Cited by 19 publications

References 41 publications

Quality of life more than 10 years after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose

Quality of life more than 10 years after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose

Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer

Radiomics for radiation oncologists: are we ready to go?

Contact Info

Product

Resources

About